-
10:06:28 PM

HGEN Stock News

08/07/23 8:01 AM
OTC : HGEN
Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
The RATinG ( R isk A dapted T herapy in Acute G vHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high-risk acute Graft versus Host Disease Planned interim assessment expected in 2024 following
RHEA-AI
neutral
06/09/23 12:05 PM
Nasdaq : HGEN
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data demonstrate statistically
RHEA-AI
neutral
07/12/22 8:30 PM
Nasdaq : HGEN
Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
Humanigen, Inc. has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases’ ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients. “We are grateful for the constructive collaboration with NIH/ NIAID; while the ACTIV-5/BET-B study...
RHEA-AI
very positive
07/06/22 8:00 AM
Nasdaq : HGEN
covid-19
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
Humanigen, Inc., a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called‘ cytokine storm,’ today announced a peer-reviewed publication in Thorax, one of the world’ s leading respiratory medicine journals and the official journal of the British Thoracic Society, describing the role of CRP in...
RHEA-AI
very positive
06/16/22 6:30 AM
Nasdaq : HGEN
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
Humanigen, Inc., a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called‘ cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services, a leading integrated global contract development manufacturing organization, to provide importation, release and...
RHEA-AI
neutral